77 related articles for article (PubMed ID: 22594272)
21. Azole susceptibility and resistance in Candida dubliniensis.
Pinjon E; Moran GP; Coleman DC; Sullivan DJ
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1210-4. PubMed ID: 16246083
[TBL] [Abstract][Full Text] [Related]
22. Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus.
Garcia-Effron G; Mellado E; Gomez-Lopez A; Alcazar-Fuoli L; Cuenca-Estrella M; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 May; 49(5):2119-21. PubMed ID: 15855543
[TBL] [Abstract][Full Text] [Related]
23. 3-imidazolyl-substituted flavans as potential antifungal agents: synthesis, stereochemical properties, and antifungal activity.
Emami S; Foroumadi A
Arch Pharm (Weinheim); 2009 Sep; 342(9):541-5. PubMed ID: 19598287
[TBL] [Abstract][Full Text] [Related]
24. Antifungal drug resistance: not all azoles are equal.
Musaji N
Expert Rev Anti Infect Ther; 2010 May; 8(5):515-6. PubMed ID: 20455680
[No Abstract] [Full Text] [Related]
25. [Activity of the azole drugs in vitro against strains of Candida albicans with different codes isolated from the digestive tract in children].
Kurnatowski M; Kurnatowska A; Wasowska-Królikowska K
Wiad Parazytol; 2004; 50(3):387-92. PubMed ID: 16865942
[TBL] [Abstract][Full Text] [Related]
26. Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
Cuenca-Estrella M; Gomez-Lopez A; Gutierrez MO; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2008 Mar; 52(3):1062-5. PubMed ID: 18195057
[TBL] [Abstract][Full Text] [Related]
27. [Mechanisms of resistance to antifungal agents].
Makimura K
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():466-70. PubMed ID: 17455664
[No Abstract] [Full Text] [Related]
28. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?
Hof H
Drug Resist Updat; 2008; 11(1-2):25-31. PubMed ID: 18325827
[TBL] [Abstract][Full Text] [Related]
29. History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action.
Shafiei M; Peyton L; Hashemzadeh M; Foroumadi A
Bioorg Chem; 2020 Nov; 104():104240. PubMed ID: 32906036
[TBL] [Abstract][Full Text] [Related]
30. Aspirochlorine class compounds from Aspergillus flavus inhibit azole-resistant Candida albicans.
Klausmeyer P; McCloud TG; Tucker KD; Cardellina JH; Shoemaker RH
J Nat Prod; 2005 Aug; 68(8):1300-2. PubMed ID: 16124785
[TBL] [Abstract][Full Text] [Related]
31. In vitro antifungal activity of sertaconazole.
Drouhet E; Dupont B
Arzneimittelforschung; 1992 May; 42(5A):705-10. PubMed ID: 1627187
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.
Mondello F; De Bernardis F; Girolamo A; Salvatore G; Cassone A
J Antimicrob Chemother; 2003 May; 51(5):1223-9. PubMed ID: 12668571
[TBL] [Abstract][Full Text] [Related]
33. A hybrid between the antifungal azole eberconazole and the alkaloid onychine.
Dombeck F; Bracher F
Pharmazie; 2005 Jan; 60(1):5-7. PubMed ID: 15700771
[TBL] [Abstract][Full Text] [Related]
34. New Progress in Azole Compounds as Antimicrobial Agents.
Zhang HZ; Gan LL; Wang H; Zhou CH
Mini Rev Med Chem; 2017; 17(2):122-166. PubMed ID: 27484625
[TBL] [Abstract][Full Text] [Related]
35. RTA2, a novel gene involved in azole resistance in Candida albicans.
Jia XM; Ma ZP; Jia Y; Gao PH; Zhang JD; Wang Y; Xu YG; Wang L; Cao YY; Cao YB; Zhang LX; Jiang YY
Biochem Biophys Res Commun; 2008 Sep; 373(4):631-6. PubMed ID: 18601908
[TBL] [Abstract][Full Text] [Related]
36. Synergy between Pyrvinium Pamoate and Azoles against Exophiala dermatitidis.
Gao L; Sun Y; He C; Zeng T; Li M
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437619
[No Abstract] [Full Text] [Related]
37. Synthesis of some new triazoles as potential antifungal agents.
Fahmy HT
Boll Chim Farm; 2001; 140(6):422-7. PubMed ID: 11822232
[TBL] [Abstract][Full Text] [Related]
38. Commercial mouthwashes are more effective than azole antifungals against Candida albicans biofilms in vitro.
Ramage G; Jose A; Coco B; Rajendran R; Rautemaa R; Murray C; Lappin DF; Bagg J
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Apr; 111(4):456-60. PubMed ID: 21310633
[TBL] [Abstract][Full Text] [Related]
39. Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
Müller FM; Staudigel A; Salvenmoser S; Tredup A; Miltenberger R; Herrmann JV
Antimicrob Agents Chemother; 2007 Aug; 51(8):3014-6. PubMed ID: 17548494
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of ME1401, a new antifungal agent.
Yamaguchi H; Uchida K; Hiratani T; Hara T; Fukuyasu H; Kazuno Y; Inouye S
Antimicrob Agents Chemother; 1986 Nov; 30(5):705-12. PubMed ID: 3800346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
